İnternet sitemizde çerez (cookie) kullanılmaktadır. Çerezler (cookie) hakkında detaylı bilgi için Çerez Politikası'nı inceleyiniz. Devam etmeniz halinde çerez (cookie) kullanımına izin verdiğinizi kabul edeceğiz. Çerez ayarlarınızı değiştirmeniz halinde internet sitesinin birtakım özelliklerini kullanamayabileceğinizi belirtmek isteriz.

Non-Hodgkin Lenfomanın tedavisinde hipertermi ve radyasyon tedavisinin birlikte uygulandığı çok merkezli deneyim

Non-Hodgkin Lenfomanın tedavisinde hipertermi ve radyasyon tedavisinin birlikte uygulandığı çok merkezli deneyim

Kategori   Hipertermi   Lenfoma   | 8.12.2016

Non-Hodgkin Lenfomanın tedavisinde hipertermi ve radyasyon tedavisinin birlikte uygulandığı çok merkezli deneyim

Multicentre experience with combined hyperthermia and radiation therapy in the treatment of superficially located non-Hodgkin's lymphomas.

 

J Exp Clin Cancer Res. 1997 Mar;16(1):87-90.

Donato V1, Zurlo A, Nappa M, Capua A, Banelli E, Martelli M, Gabriele P, Amichetti M, Biagini C.

Author information

• 1 Institute of Radiology, University of Rome La Sapienza.

Abstract

The combination of Radiation Therapy (RT) and Hyperthermia (HT) has proved to be an effective treatment for a wide variety of superficially located recurrences of different tumors, particularly those arising in previously irradiated areas. Few studies on the use of HT in the management of lymphomatous diseases have so far obtained interesting results. Eight patients with Non Hodgkin Lymphomas (LNH) - 4 with cutaneous lymphomas and 4 with nodal recurrences after RT-Chemotherapy (CHT) treatment treated in three different Italian institutions with combined RT and HT are here reported. Rt dose ranged from 15 to 40 Gy with different fractionations, on the basis of previously received treatment. Hyperthermia was delivered using 432 or 915 MHz external microwave applicators, according to extension and depth of the lesions and available equipment. All patients tolerated well the HT treatment, and in all cases average intratumoral temperatures were >42 degrees, with 3 out of 10 treated sites achieving the goal of average temperatures >42.5%. One patient, with recurrent NHL, is disease-free after 24 months from completion of combined therapy. Our results seem to confirm previous experiences, suggesting a role of HT/RT not only for palliative purposes in cutaneous lymphomas, but also as an adjunct to radiotherapy alone in selected patients with superficially located recurrences.